Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Neurosci
2010 Jun 02;3022:7575-86. doi: 10.1523/JNEUROSCI.1312-10.2010.
Show Gene links
Show Anatomy links
The DREAM protein negatively regulates the NMDA receptor through interaction with the NR1 subunit.
Zhang Y
,
Su P
,
Liang P
,
Liu T
,
Liu X
,
Liu XY
,
Zhang B
,
Han T
,
Zhu YB
,
Yin DM
,
Li J
,
Zhou Z
,
Wang KW
,
Wang Y
.
Abstract
Glutamate-induced excitotoxicity has been implicated in the etiology of stroke, epilepsy, and neurodegenerative diseases. NMDA receptors (NMDARs) play a pivotal role in excitotoxic injury; however, clinical trials testing NMDAR antagonists as neuroprotectants have been discouraging. The development of novel neuroprotectant molecules is being vigorously pursued. Here, we report that downstream regulatory element antagonist modulator (DREAM) significantly inhibits surface expression of NMDARs and NMDAR-mediated current. Overexpression of DREAM showed neuroprotection against excitotoxic neuronal injury, whereas knockdown of DREAM enhanced NMDA-induced toxicity. DREAM could directly bind to the C0 domain of the NR1 subunit. Although DREAM contains multiple binding sites for the NR1 subunit, residues 21-40 of the N terminus are the main binding site for the NR1 subunit. Thus, 21-40 residues might relieve the autoinhibition conferred by residues 1-50 and derepress the DREAM core domain by a competitive mechanism. Intriguingly, the cell-permeable TAT-21-40 peptide, constructed according to the critical binding site of DREAM to the NR1 subunit, inhibits NMDAR-mediated currents in primary cultured hippocampal neurons and has a neuroprotective effect on in vitro neuronal excitotoxic injury and in vivo ischemic brain damage. Moreover, both pretreatment and posttreatment of TAT-21-40 is effective against excitotoxicity. In summary, this work reveals a novel, negative regulator of NMDARs and provides an attractive candidate for the treatment of excitotoxicity-related disease.
Aarts,
Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions.
2002, Pubmed
Aarts,
Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions.
2002,
Pubmed
Akyol,
Apo-calmodulin binds with its C-terminal domain to the N-methyl-D-aspartate receptor NR1 C0 region.
2004,
Pubmed
Alexander,
The role of calsenilin/DREAM/KChIP3 in contextual fear conditioning.
2009,
Pubmed
An,
Modulation of A-type potassium channels by a family of calcium sensors.
2000,
Pubmed
,
Xenbase
Brackmann,
Neuronal Ca2+ sensor protein VILIP-1 affects cGMP signalling of guanylyl cyclase B by regulating clathrin-dependent receptor recycling in hippocampal neurons.
2005,
Pubmed
Bradley,
Splice variants of the NR1 subunit differentially induce NMDA receptor-dependent gene expression.
2006,
Pubmed
Burgoyne,
Neuronal calcium sensor proteins: generating diversity in neuronal Ca2+ signalling.
2007,
Pubmed
Buxbaum,
Calsenilin: a calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment.
1998,
Pubmed
Carrión,
DREAM is a Ca2+-regulated transcriptional repressor.
1999,
Pubmed
Cheng,
DREAM is a critical transcriptional repressor for pain modulation.
2002,
Pubmed
Choi,
Phosphorylation of calsenilin at Ser63 regulates its cleavage by caspase-3.
2003,
Pubmed
Choi,
Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists.
1988,
Pubmed
Coussen,
Co-assembly of two GluR6 kainate receptor splice variants within a functional protein complex.
2005,
Pubmed
D Burgoyne,
The neuronal calcium-sensor proteins.
2004,
Pubmed
D'Andrea,
The transcriptional repressor DREAM is involved in thyroid gene expression.
2005,
Pubmed
Ehlers,
Inactivation of NMDA receptors by direct interaction of calmodulin with the NR1 subunit.
1996,
Pubmed
Ehlers,
Splice variant-specific interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments.
1998,
Pubmed
Flowerdew,
A VAMP7/Vti1a SNARE complex distinguishes a non-conventional traffic route to the cell surface used by KChIP1 and Kv4 potassium channels.
2009,
Pubmed
Fontán-Lozano,
Lack of DREAM protein enhances learning and memory and slows brain aging.
2009,
Pubmed
Gomez-Villafuertes,
Downstream regulatory element antagonist modulator regulates Ca2+ homeostasis and viability in cerebellar neurons.
2005,
Pubmed
Haynes,
Interaction of neuronal calcium sensor-1 and ADP-ribosylation factor 1 allows bidirectional control of phosphatidylinositol 4-kinase beta and trans-Golgi network-plasma membrane traffic.
2005,
Pubmed
Ivings,
Identification of Ca2+-dependent binding partners for the neuronal calcium sensor protein neurocalcin delta: interaction with actin, clathrin and tubulin.
2002,
Pubmed
Jerng,
Multiple Kv channel-interacting proteins contain an N-terminal transmembrane domain that regulates Kv4 channel trafficking and gating.
2008,
Pubmed
Krupp,
Interactions of calmodulin and alpha-actinin with the NR1 subunit modulate Ca2+-dependent inactivation of NMDA receptors.
1999,
Pubmed
Leonard,
Calcium/calmodulin-dependent protein kinase II is associated with the N-methyl-D-aspartate receptor.
1999,
Pubmed
Leonard,
Regulation of calcium/calmodulin-dependent protein kinase II docking to N-methyl-D-aspartate receptors by calcium/calmodulin and alpha-actinin.
2002,
Pubmed
Lilliehook,
Altered Abeta formation and long-term potentiation in a calsenilin knock-out.
2003,
Pubmed
Lin,
The calcium sensor protein visinin-like protein-1 modulates the surface expression and agonist sensitivity of the alpha 4beta 2 nicotinic acetylcholine receptor.
2002,
Pubmed
,
Xenbase
Lin,
Yotiao, a novel protein of neuromuscular junction and brain that interacts with specific splice variants of NMDA receptor subunit NR1.
1998,
Pubmed
Link,
Day-night changes in downstream regulatory element antagonist modulator/potassium channel interacting protein activity contribute to circadian gene expression in pineal gland.
2004,
Pubmed
Liu,
NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo.
2007,
Pubmed
Mayanagi,
Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia.
2008,
Pubmed
Merrill,
Displacement of alpha-actinin from the NMDA receptor NR1 C0 domain By Ca2+/calmodulin promotes CaMKII binding.
2007,
Pubmed
Palmer,
Hippocalcin functions as a calcium sensor in hippocampal LTD.
2005,
Pubmed
Rivas,
The DREAM protein is associated with thyroid enlargement and nodular development.
2009,
Pubmed
Rodriguez,
A simplified procedure for the quantitative measurement of neurological deficits after forebrain ischemia in mice.
2005,
Pubmed
Sanz,
Interleukin 3-dependent activation of DREAM is involved in transcriptional silencing of the apoptotic Hrk gene in hematopoietic progenitor cells.
2001,
Pubmed
Sattler,
Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death.
2001,
Pubmed
Savignac,
Transcriptional repressor DREAM regulates T-lymphocyte proliferation and cytokine gene expression.
2005,
Pubmed
Scott,
Endocytosis and degradative sorting of NMDA receptors by conserved membrane-proximal signals.
2004,
Pubmed
,
Xenbase
Wechsler,
Brain spectrin binding to the NMDA receptor is regulated by phosphorylation, calcium and calmodulin.
1998,
Pubmed
Weiss,
Neuronal Ca2+ sensor-1/frequenin functions in an autocrine pathway regulating Ca2+ channels in bovine adrenal chromaffin cells.
2000,
Pubmed
Wexler,
An objective procedure for ischemic area evaluation of the stroke intraluminal thread model in the mouse and rat.
2002,
Pubmed
Wyszynski,
Competitive binding of alpha-actinin and calmodulin to the NMDA receptor.
1997,
Pubmed
Zhou,
Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors.
2006,
Pubmed
van Rossum,
Dynamic interaction between soluble tubulin and C-terminal domains of N-methyl-D-aspartate receptor subunits.
1999,
Pubmed
